340 related articles for article (PubMed ID: 28586717)
1. Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a "joint action" mode toward DNA.
Qin X; Fang L; Chen F; Gou S
Eur J Med Chem; 2017 Sep; 137():167-175. PubMed ID: 28586717
[TBL] [Abstract][Full Text] [Related]
2. Toward overcoming cisplatin resistance via sterically hindered platinum(II) complexes.
Yu H; Gou S; Wang Z; Chen F; Fang L
Eur J Med Chem; 2016 May; 114():141-52. PubMed ID: 26974381
[TBL] [Abstract][Full Text] [Related]
3. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
[TBL] [Abstract][Full Text] [Related]
4. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
Xu Z; Hu W; Wang Z; Gou S
Eur J Med Chem; 2017 Dec; 141():211-220. PubMed ID: 29031068
[TBL] [Abstract][Full Text] [Related]
5. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.
Liu Z; Wang M; Wang H; Fang L; Gou S
Eur J Med Chem; 2020 May; 194():112269. PubMed ID: 32248002
[TBL] [Abstract][Full Text] [Related]
6. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
Montagner D; Tolan D; Andriollo E; Gandin V; Marzano C
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486477
[TBL] [Abstract][Full Text] [Related]
7. Hybrid of DNA-targeting Chlorambucil with Pt(IV) Species to Reverse Drug Resistance.
Chen F; Xu G; Qin X; Jin X; Gou S
J Pharmacol Exp Ther; 2017 Nov; 363(2):221-239. PubMed ID: 28916659
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, Cytotoxicity, and Mechanistic Investigation of Platinum(IV) Anticancer Complexes Conjugated with Poly(ADP-ribose) Polymerase Inhibitors.
Xu Z; Li C; Zhou Q; Deng Z; Tong Z; Tse MK; Zhu G
Inorg Chem; 2019 Dec; 58(23):16279-16291. PubMed ID: 31738050
[TBL] [Abstract][Full Text] [Related]
9. Construction of Dual Stimuli-Responsive Platinum(IV) Hybrids with NQO1 Targeting Ability and Overcoming Cisplatin Resistance.
Fang L; Qin X; Zhao J; Gou S
Inorg Chem; 2019 Feb; 58(3):2191-2200. PubMed ID: 30657321
[TBL] [Abstract][Full Text] [Related]
10. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
Huang X; Wang M; Wang C; Hu W; You Q; Yang Y; Yu C; Liao Z; Gou S; Wang H
Bioorg Chem; 2019 Nov; 92():103236. PubMed ID: 31494328
[TBL] [Abstract][Full Text] [Related]
11. Sterically hindered complexes of platinum(II) with planar heterocyclic nitrogen donors. A novel complex with 1-methyl-cytosine has a spectrum of activity different from cisplatin and is able of overcoming acquired cisplatin resistance.
Margiotta N; Natile G; Capitelli F; Fanizzi FP; Boccarelli A; De Rinaldis P; Giordano D; Coluccia M
J Inorg Biochem; 2006 Nov; 100(11):1849-57. PubMed ID: 16959321
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, cytotoxicity and antitumor activity of platinum(II) complexes of cyclopentanecarboxylic acid hydrazide.
Kushev D; Gorneva G; Taxirov S; Spassovska N; Grancharov K
Biol Chem; 1999 Nov; 380(11):1287-94. PubMed ID: 10614821
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, characterization and biological investigation of platinum(ii) complexes with asparagusic acid derivatives as ligands.
Hildebrandt J; Trautwein R; Kritsch D; Häfner N; Görls H; Dürst M; Runnebaum IB; Weigand W
Dalton Trans; 2019 Jan; 48(3):936-944. PubMed ID: 30565617
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, characterization, and biological evaluation of new tetrazole-based platinum(II) and palladium(II) chlorido complexes--potent cisplatin analogues and their trans isomers.
Serebryanskaya TV; Yung T; Bogdanov AA; Shchebet A; Johnsen SA; Lyakhov AS; Ivashkevich LS; Ibrahimava ZA; Garbuzenco TS; Kolesnikova TS; Melnova NI; Gaponik PN; Ivashkevich OA
J Inorg Biochem; 2013 Mar; 120():44-53. PubMed ID: 23305964
[TBL] [Abstract][Full Text] [Related]
15. Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.
Ratzon E; Najajreh Y; Salem R; Khamaisie H; Ruthardt M; Mahajna J
BMC Cancer; 2016 Feb; 16():140. PubMed ID: 26906901
[TBL] [Abstract][Full Text] [Related]
16. Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance.
Chen Q; Yang Y; Lin X; Ma W; Chen G; Li W; Wang X; Yu Z
Chem Commun (Camb); 2018 May; 54(42):5369-5372. PubMed ID: 29744485
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity profile of novel sterically hindered platinum(II) complexes with (1R,2R)-N(1),N(2)-dibutyl-1,2-diaminocyclohexane.
Zhang H; Gou S; Zhao J; Chen F; Xu G; Liu X
Eur J Med Chem; 2015; 96():187-95. PubMed ID: 25874342
[TBL] [Abstract][Full Text] [Related]
18. Polyphosphoester conjugates of dinuclear platinum complex: synthesis and evaluation of cytotoxic and the proapoptotic activity.
Mitova V; Slavcheva S; Shestakova P; Momekova D; Stoyanov N; Momekov G; Troev K; Koseva N
Eur J Med Chem; 2014 Jan; 72():127-36. PubMed ID: 24361525
[TBL] [Abstract][Full Text] [Related]
19. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
Siddik ZH; al-Baker S; Thai G; Khokhar AR
Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
[TBL] [Abstract][Full Text] [Related]
20. A Novel Platinum-based Compound with Preferential Cytotoxic Activity against a Panel of Cancer Cell Lines.
Shahsavar F; Bozorgmehr M; Mirzadegan E; Abedi A; Lighvan ZM; Mohammadi F; Safari N; Amani V; Zarnani AH
Anticancer Agents Med Chem; 2016; 16(3):393-403. PubMed ID: 26899296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
